Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease-Reference-Cited by-同舟云学术

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

Published:2024-06-20 Issue:7 Volume:84 Page:811-823
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hey John A.^ORCID,Abushakra Susan,Blennow Kaj,Reiman Eric M.,Hort Jakub,Prins Niels D.,Sheardova Katerina,Kesslak Patrick,Shen Larry,Zhu Xinyi,Albayrak Adem,Paul Jijo,Schaefer Jean F.,Power Aidan,Tolar Martin

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40265-024-02067-8.pdf

Reference57 articles.

1. Alzheimer’s Association Facts and Figures. 2024. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf.

2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3. https://doi.org/10.1126/science.8346443.

3. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400. https://doi.org/10.1146/annurev.med.47.1.387.

4. Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of Apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38:1–17. https://doi.org/10.1159/000334607.

5. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21. https://doi.org/10.1056/NEJMoa2212948.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease;Med;2024-09

2. APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-07

3. Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model;Drugs;2024-06-20

4. Deep Learning Applications in MRI-Based Detection of the Hippocampal Region for Alzheimer’s Diagnosis;IEEE Access;2024